- 50 milion people in the world and 3 million people in Europe are affected by inflammatory bowel disease (IBD), which has a direct healthcare cost of 4.6 to 5.6 billion euros per year.
- Diagnosis of IBD such as Crohn’s disease and ulcerative colitis tends to be slow and based on vague clinical parameters.
- In addition to IBD, irritable bowel syndrome (IBS) is one of the 10 most difficult diseases to identify according to Fleming’s list.
- It is estimated that up to 45% of patients wait more than one year for a diagnosis for these pathologies, whilst up to 17% wait more than five years.
IBD and IBS are characterised by intermittent periods of flare-ups and no activity or remission, complicating follow-up with aggressive treatment and invasive techniques.
Thanks to our disruptive RAID-CD, an efficient, rapid and non-invasive diagnosis can be carried out by way of a stool test with high sensitivity and specificity to distinguish between Crohn’s disease, ulcerative colitis and irritable bowel syndrome, without the need for a colonoscopy.
Treatment prediction: microbiological balance can determine response to therapeutic approach such as anti-TNF treatment or post-surgery relapse in Crohn’s disease patient. Through the specific bacterial signature of RAID-CD we are able to determine its response before patient start treatment what helps to efficiently deal with therapeutic pauta.
RAID-CD will significantly improve the quality of life of patients.
Jornada “Empreses Emergents i Finançament” StartUp Girona Dia/Mes: 8 de novembre Hora: 12:25 ...
25th UEG Week Barcelona 2017 Day/Month: October 28 – November 1, 2017 Place: Fira Gran ...
GoodGut has moved to a new space at Science and Technology Park of ...